Merck KGaA nabs FDA "Breakthrough" tag for MET-targeting lun...

The FDA thinks German Merck could have a breakthrough in its hands with a new lung cancer drug that targets aggressive tumours with a mutation known as MET.

Relief for Lilly as drug from $8bn Loxo deal clears pivotal ...

Mixed reviews for Amgen's KRAS drug after lung cancer data r...

Eagerly awaited trial data from Amgen’s latest KRAS-targeting cancer drug AMG 510 emerged over the weekend – and the results have received broadly positive reviews.

Novartis' lung cancer drug edges closer to market after FDA ...

An investigational lung cancer drug from Novartis and Incyte could be on the market midway through next year after the FDA agreed to expedite development and review in a tough to treat form

Rova-T: the story of AbbVie’s multi-billion dollar failure

Richard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Stemcentrx and its lung cancer drug Rova-T.

AZ gets China nod for Tagrisso in first-line lung cancer